Retatrutide vs Tirzepatide vs Semaglutide: How They Differ

Three incretin-targeting compounds dominate current metabolic research interest: semaglutide, tirzepatide, and retatrutide. They are often grouped together as GLP-1 drugs, but the three differ meaningfully at the receptor level. Semaglutide targets one receptor, tirzepatide two, and retatrutide three. That distinction, and the development stage behind each, is the core of the comparison.

One Receptor: Semaglutide

Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, increasing insulin release when blood sugar is elevated, slowing gastric emptying, and reducing appetite through fullness signals to the brain. It is the only one of the three with approved oral and injectable forms: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for weight management, with cardiovascular and MASH indications across the brands. In the SELECT trial, semaglutide reduced major adverse cardiovascular events by 20% in adults with obesity and established cardiovascular disease, independent of diabetes status.

Two Receptors: Tirzepatide

Tirzepatide adds a second target: the glucose-dependent insulinotropic polypeptide (GIP) receptor. As a dual GLP-1/GIP agonist it activates both incretin pathways in a single molecule. In the approved programs it is delivered as a weekly injection: Mounjaro for type 2 diabetes and Zepbound for weight management and obstructive sleep apnea in eligible adults. Head-to-head trial data have reported greater blood sugar reduction and weight loss with the dual agonist than with a GLP-1-only comparator, the finding that underpins the positioning of the compound.

Three Receptors: Retatrutide

Retatrutide is the investigational triple agonist, activating GLP-1, GIP, and glucagon receptors in one molecule. The additional glucagon receptor activity distinguishes it from both approved compounds: where the first two primarily reduce appetite and improve glycaemic control, the glucagon component is under investigation for increasing energy expenditure. Retatrutide has no regulatory approval. It is being evaluated in the Phase 3 TRIUMPH program; in TRIUMPH-1 topline results reported in May 2026, the 12 mg dose produced an average weight loss of 28% over 80 weeks among participants who stayed on treatment. Further readouts, including TRIUMPH-2 in type 2 diabetes and TRIUMPH-3 in established cardiovascular disease, are expected later this year.

What the Differences Mean for Researchers

For researchers, the practical takeaway is development stage as much as mechanism. Semaglutide and tirzepatide have mature safety datasets from approved use and long-term outcome studies. Retatrutide remains a Phase 3 compound, with tolerability data still accumulating; digestive side effects have been the most commonly reported across the class, with heart rate increases reported in some retatrutide trials. Cross-trial comparisons should be treated cautiously given differences in study design and populations. The comparison matters most when designing experiments: single-receptor agonism, dual GIP/GLP-1 signalling, and triple GLP-1/GIP/glucagon activation each create pharmacodynamic profiles worth modelling separately.

For educational purposes only. This content is informational and reflects publicly reported research developments. It is not medical advice and makes no therapeutic claims. Products referenced are for research use only. Consult a qualified healthcare professional for any medical question.